PubMed · 1992 · 158 citations · 13 references
MedicineGeneticsMolecular GeneticsCancer GeneticsMolecular OncologyNeoplasiaCancer GenomicsMammary TumorsMolecular Tumor ProfilingMalignant Breast TumorsP53 AbnormalityP53 MutationProgesterone Receptor StatusSingle Nucleotide Variant AnalysisSingle-nucleotide VariantsTp53 MutationsTumor Suppressor P53
Using a polymerase chain reaction-single strand conformation polymorphism approach we analyzed 96 human primary breast tumors for the presence of mutations in exons 2, 5, 6, 7, 8, and 9 of the p53 gene. These exons have been shown to comprise highly conserved sequences and the portion including exons 5 through 9 is believed to be the target for over 90% of the acquired mutations in human cancer. Eighteen tumors of the 96 (18.7%) tested showed reproducibly a variant band indicative of a mutation. Most (15 tumors) of the mutations were single nucleotide substitutions and G:C to A:T transitions were prevalent (6 tumors), G:C to T:A transversions came next (4 tumors), and guanines were always on the nontranscribed strand. Concomitant loss of the wild type allele and mutation of the other copy was observed in only 3 of 18 mutated cases; this is consistent with the heterogeneous cellular composition of breast tumors. Furthermore p53 mutations were correlated to estrogen and/or progesterone receptor negative tumors, thus indicating their relationships to aggressive breast cancer. No association could be observed with DNA amplification events in these tumors.
13
Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations
The p53 proto-oncogene can act as a suppressor of transformation
Cathy A. Finlay, Philip W. Hinds, Arnold J. Levine · Cell · 1989 · 2K citations
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
Jiří Bártek, Richard Iggo, Julian Gannon et al. · PubMed · 1990 · 606 citations
Life Sciences, Genetics, Oncology +13